EU/3/15/1516

About

On 28 July 2015, orphan designation (EU/3/15/1516) was granted by the European Commission to Lokon Pharma AB, Sweden, for modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL for the treatment of pancreatic cancer.

The sponsor’s address was updated in June 2020.

Key facts

Active substance
Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL
Disease / condition
Treatment of pancreatic cancer
Date of first decision
28/07/2015
Outcome
Positive
EU designation number
EU/3/15/1516

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Lokon Pharma AB
Bredgrand 14
Uppsala Domkyrkofors.
Uppsala 753 20
Uppsala Lan
Sweden
Tel: +46735377161
E-mail: angelica.loskog@nxt2b.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating